DeepMed Research

YOKOHAMA CITY UNIVERSITY

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1882-01-01

Employees: -

Market Cap: -

Website: http://www.yokohama-cu.ac.jp

Clinical Trials

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

Phase 2

Active, not recruiting

Conditions: Non Alcoholic Fatty Liver Disease

Interventions: Drug: Pemafibrate low dose
Drug: Fenofibrate
Drug: Pemafibrate high dose

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Yokohama City University

Target Recruit Count: 360

Registration Number: NCT06623539

Locations: 🇯🇵
Yokohama city university, Yokohama, Kanagawa, Japan

Elobixibat for Chronic Constipation Without Defecation Desire

Phase 4

Conditions: Chronic Constipation

Interventions: Drug: Elobixibat 10mg

First Posted Date: 2021-12-21

Last Posted Date: 2022-03-23

Lead Sponsor: Yokohama City University

Target Recruit Count: 40

Registration Number: NCT05165199

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease

Phase 2

Active, not recruiting

Conditions: Nonalcoholic Fatty Liver
Nonalcoholic Steatohepatitis

First Posted Date: 2021-10-19

Last Posted Date: 2022-09-27

Lead Sponsor: Yokohama City University

Target Recruit Count: 29

Registration Number: NCT05084404

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

Long-term Elobixibat for Chronic Constipation

Phase 4

Recruiting

Conditions: Chronic Constipation

Interventions: Drug: Elobixibat 10mg
Drug: Placebo

First Posted Date: 2021-03-05

Last Posted Date: 2023-01-05

Lead Sponsor: Yokohama City University

Target Recruit Count: 100

Registration Number: NCT04784780

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver

Interventions: Drug: Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
Drug: Elobixibat placebo + cholestyramine powder placebo
Drug: Elobixibat 10mg + cholestyramine powder placebo
Drug: Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)

First Posted Date: 2020-01-21

Last Posted Date: 2021-11-16

Lead Sponsor: Yokohama City University

Target Recruit Count: 102

Registration Number: NCT04235205

Locations: 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan

Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

Phase 2

Conditions: Chronic Intestinal Pseudo-obstruction

Interventions: Drug: Rifaximin oral tablet
Drug: Placebo oral tablet

First Posted Date: 2019-10-08

Last Posted Date: 2021-06-21

Lead Sponsor: Yokohama City University

Target Recruit Count: 12

Registration Number: NCT04118699

Locations: 🇯🇵
Yokohama city university, Yokohama, Kanagawa, Japan

Shared Decision Making for Patients With First-admission Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Behavioral: Shared Decision Making

First Posted Date: 2013-06-05

Last Posted Date: 2015-12-30

Lead Sponsor: Yokohama City University

Target Recruit Count: 23

Registration Number: NCT01869660

Locations: 🇯🇵
Numazu Chuou Hospital, Numazu, Shizuoka, Japan

S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer

Phase 3

Conditions: Head and Neck Cancer

First Posted Date: 2006-06-15

Last Posted Date: 2013-05-15

Lead Sponsor: Yokohama City University

Target Recruit Count: 500

Registration Number: NCT00336947

Locations: 🇯🇵
National Hospital Organization - Himeji Medical Center, Himeji-shi, Hyogo, Japan
🇯🇵
Fujita Health University, Toyoake, Aichi, Japan
🇯🇵
Mie University Graduate School of Medicine, Tsu, Mie, Japan

and more 45 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy